Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats

Diabetes mellitus is recognized as a risk factor for sarcopenia. Luseogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces inflammation and oxidative stress by improving hyperglycemia, subsequently improving hepatosteatosis or kidney dysfunction. However, the effects of S...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Keyu, Sugimoto, Ken, Tanaka, Minoru, Akasaka, Hiroshi, Fujimoto, Taku, Takahashi, Toshimasa, Onishi, Yuri, Minami, Tomohiro, Yoshida, Shino, Takami, Yoichi, Yamamoto, Koichi, Rakugi, Hiromi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209601/
https://www.ncbi.nlm.nih.gov/pubmed/37251965
http://dx.doi.org/10.3164/jcbn.22-58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209601/
https://www.ncbi.nlm.nih.gov/pubmed/37251965
http://dx.doi.org/10.3164/jcbn.22-58

Ejemplares similares